Serious Adverse Events of Oral and Topical Carbonic Anhydrase Inhibitors.

ABSTRACT:

Importance

Some ophthalmologists may be reluctant to prescribe oral carbonic anhydrase inhibitors, given the potential for life-threatening systemic adverse reactions.

Objective

To conduct a population-based analysis of the safety of oral or topical carbonic anhydrase inhibitors in clinical care.

Design, setting, and participants

This matched longitudinal cohort study took place in Ontario, Canada. Consecutive patients older than 65 years who were prescribed an oral or topical carbonic anhydrase inhibitor in Ontario, Canada, between January 1, 1995, and January 1, 2020, were identified. Patients were matched 1-to-1 based on age, sex, and diabetes status. Time zero was defined as the date of the first identified prescription for the medication, and the primary analysis

SUBMITTER: Popovic MM 

PROVIDER: S-EPMC8796060 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature